Journal ArticleDOI
ASCO 2006 Update of Recommendations for the Use of Tumor Markers in Gastrointestinal Cancer
Gershon Y. Locker,Stanley R Hamilton,Jules Harris,John M. Jessup,Nancy E. Kemeny,John S. Macdonald,Mark R. Somerfield,Daniel F. Hayes,Robert C. Bast +8 more
Reads0
Chats0
TLDR
It is recommended that carcinoembryonic antigen (CEA) be ordered preoperatively, if it would assist in staging and surgical planning, and data are insufficient to recommend the routine use of p53, ras, thymidine synthase, dihydropyrimidine dehydrogenase,Thymidine phosphorylase, microsatellite instability, 18q loss of heterozygosity, or deleted in colon cancer (DCC) protein in the management of patients with colAbstract:
Purpose To update the recommendations for the use of tumor marker tests in the prevention, screening, treatment, and surveillance of gastrointestinal cancers. Methods For the 2006 update, an update committee composed of members from the full Panel was formed to complete the review and analysis of data published since 1999. Computerized literature searches of Medline and the Cochrane Collaboration Library were performed. The Update Committee’s literature review focused attention on available systematic reviews and meta-analyses of published tumor marker studies.read more
Citations
More filters
Journal ArticleDOI
Glypican-1 identifies cancer exosomes and detects early pancreatic cancer
Sonia A. Melo,Linda B. Luecke,Christoph Kahlert,Agustín F. Fernández,Seth T. Gammon,Judith Kaye,Valerie S. LeBleu,Elizabeth A. Mittendorf,Juergen Weitz,Nuh N. Rahbari,Christoph Reissfelder,Christian Pilarsky,Mario F. Fraga,David Piwnica-Worms,Raghu Kalluri +14 more
TL;DR: GPC1+ crExos may serve as a potential non-invasive diagnostic and screening tool to detect early stages of pancreatic cancer to facilitate possible curative surgical therapy.
Journal ArticleDOI
Glycosylation in cancer: mechanisms and clinical implications
Salomé S. Pinho,Celso A. Reis +1 more
TL;DR: The roles of glycans are highlighted by the fact that alterations in glycosylation regulate the development and progression of cancer, serving as important biomarkers and providing a set of specific targets for therapeutic intervention.
Journal ArticleDOI
Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
Federica Di Nicolantonio,Miriam Martini,Francesca Molinari,Andrea Sartore-Bianchi,Sabrina Arena,Piercarlo Saletti,Sara De Dosso,Luca Mazzucchelli,Milo Frattini,Salvatore Siena,Alberto Bardelli +10 more
TL;DR: BRAF wild-type is required for response to panitumumab or cetuximab and could be used to select patients who are eligible for the treatment and should be used for selection.
Journal ArticleDOI
International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study
Franck Pagès,Bernhard Mlecnik,Florence Marliot,Gabriela Bindea,Gabriela Bindea,Gabriela Bindea,Fang Shu Ou,Carlo Bifulco,Alessandro Lugli,Inti Zlobec,Tilman T. Rau,Martin D. Berger,Iris D. Nagtegaal,Elisa Vink-Börger,Arndt Hartmann,Carol Geppert,Julie Kolwelter,Susanne Merkel,Robert Grützmann,Marc Van den Eynde,Anne Jouret-Mourin,Alex Kartheuser,Daniel Léonard,Christophe Remue,Julia Y. Wang,Julia Y. Wang,Prashant Bavi,Michael H.A. Roehrl,Michael H.A. Roehrl,Michael H.A. Roehrl,Pamela S. Ohashi,Linh T. Nguyen,Seong Jun Han,Heather L. MacGregor,Sara Hafezi-Bakhtiari,Bradly G. Wouters,Giuseppe Masucci,Emilia Andersson,Eva Zavadova,Michal Vocka,Jan Spacek,Lubos Petruzelka,Bohuslav Konopasek,Pavel Dundr,Helena Skalova,Kristyna Nemejcova,Gerardo Botti,Fabiana Tatangelo,Paolo Delrio,Gennaro Ciliberto,Michele Maio,Luigi Laghi,Fabio Grizzi,Tessa Fredriksen,Tessa Fredriksen,Tessa Fredriksen,Bénédicte Buttard,Bénédicte Buttard,Bénédicte Buttard,Mihaela Angelova,Mihaela Angelova,Mihaela Angelova,Angela Vasaturo,Angela Vasaturo,Angela Vasaturo,Pauline Maby,Pauline Maby,Pauline Maby,Sarah E. Church,Helen K. Angell,Lucie Lafontaine,Lucie Lafontaine,Lucie Lafontaine,Daniela Bruni,Daniela Bruni,Daniela Bruni,Carine El Sissy,Nacilla Haicheur,Amos Kirilovsky,Anne Berger,Christine Lagorce,Jeffrey P. Meyers,Christopher Paustian,Zipei Feng,Carmen Ballesteros-Merino,Jeroen R. Dijkstra,Carlijn van de Water,Shannon van Vliet,Nikki Knijn,Ana Maria Mușină,Dragos Viorel Scripcariu,Boryana Popivanova,Mingli Xu,Tomonobu Fujita,Shoichi Hazama,Nobuaki Suzuki,Hiroaki Nagano,Kiyotaka Okuno,Toshihiko Torigoe,Noriyuki Sato,Tomohisa Furuhata,Ichiro Takemasa,Kyogo Itoh,P. Patel,Hemangini H. Vora,Birva Shah,Jayendrakumar B. Patel,Kruti N. Rajvik,Shashank J. Pandya,Shilin N. Shukla,Yili Wang,Guanjun Zhang,Yutaka Kawakami,Francesco M. Marincola,Paolo A. Ascierto,Daniel J. Sargent,Bernard A. Fox,Bernard A. Fox,Jérôme Galon,Jérôme Galon,Jérôme Galon +120 more
TL;DR: The immunoscore provides a reliable estimate of the risk of recurrence in patients with colon cancer and supports the implementation of the consensus Immunoscore as a new component of a TNM-Immune classification of cancer.
Journal ArticleDOI
Towards the introduction of the 'Immunoscore' in the classification of malignant tumours.
Jérôme Galon,Jérôme Galon,Jérôme Galon,Bernhard Mlecnik,Bernhard Mlecnik,Bernhard Mlecnik,Gabriela Bindea,Gabriela Bindea,Gabriela Bindea,Helen K. Angell,Helen K. Angell,Helen K. Angell,Anne Berger,Christine Lagorce,Alessandro Lugli,Inti Zlobec,Arndt Hartmann,Carlo Bifulco,Iris D. Nagtegaal,Richard Palmqvist,Giuseppe Masucci,Gerardo Botti,Fabiana Tatangelo,Paolo Delrio,Michele Maio,Luigi Laghi,Fabio Grizzi,Martin Asslaber,Corrado D'Arrigo,Fernando Vidal-Vanaclocha,Eva Zavadova,Lotfi Chouchane,Pamela S. Ohashi,Sara Hafezi-Bakhtiari,Bradly G. Wouters,Michael H.A. Roehrl,Linh V. Nguyen,Yutaka Kawakami,Shoichi Hazama,Kiyotaka Okuno,Shuji Ogino,Peter Gibbs,Paul Waring,Noriyuki Sato,Toshihiko Torigoe,Kyogo Itoh,P. Patel,Shilin N. Shukla,Yili Wang,Scott Kopetz,Frank A. Sinicrope,Viorel Scripcariu,Paolo A. Ascierto,Francesco M. Marincola,Bernard A. Fox,Bernard A. Fox,Franck Pagès +56 more
TL;DR: In colorectal cancer, the Immunoscore may add to the significance of the current AJCC/UICC TNM classification, since it has been demonstrated to be a prognostic factor superior to the AJCC or UICCTNM classification.
References
More filters
Journal ArticleDOI
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
Herbert Hurwitz,Louis Fehrenbacher,William Novotny,Thomas Cartwright,John D. Hainsworth,W. Heim,Jordan Berlin,Ari David Baron,Susan Griffing,Eric Holmgren,Napoleone Ferrara,Gwen Fyfe,Beth Rogers,Robert W. Ross,Fairooz F. Kabbinavar +14 more
TL;DR: The addition of bevacizumab to fluorouracil-based combination chemotherapy results in statistically significant and clinically meaningful improvement in survival among patients with metastatic colorectal cancer.
Journal ArticleDOI
Genetic alterations during colorectal-tumor development.
Bert Vogelstein,Eric R. Fearon,Stanley R. Hamilton,Scott E. Kern,Ann C. Preisinger,Mark Leppert,A M Smits,Johannes L. Bos +7 more
TL;DR: It is found that ras-gene mutations occurred in 58 percent of adenomas larger than 1 cm and in 47 percent of carcinomas, which are consistent with a model of colorectal tumorigenesis in which the steps required for the development of cancer often involve the mutational activation of an oncogene coupled with the loss of several genes that normally suppress tumors.
Journal Article
A National Cancer Institute Workshop on Microsatellite Instability for Cancer Detection and Familial Predisposition: Development of International Criteria for the Determination of Microsatellite Instability in Colorectal Cancer
C. Richard Boland,Stephen N. Thibodeau,Stanley R. Hamilton,David Sidransky,James R. Eshleman,Randall W. Burt,Stephen J. Meltzer,Miguel A. Rodriguez-Bigas,Riccardo Fodde,G. Nadia Ranzani,Sudhir Srivastava +10 more
TL;DR: The spectrum of microsatellite alterations in noncolonic tumors was reviewed, and it was concluded that the above recommendations apply only to colorectal neoplasms.
Journal ArticleDOI
Clinical Score for Predicting Recurrence After Hepatic Resection for Metastatic Colorectal Cancer: Analysis of 1001 Consecutive Cases
TL;DR: There is a need for clearly defined and widely applicable clinical criteria for the selection of patients who may benefit from hepatic resection for metastatic colorectal cancer and studies of preoperative staging techniques or of adjuvant therapies should consider using such a score for stratification of patients.
Journal ArticleDOI
Microsatellite instability in cancer of the proximal colon
TL;DR: Colorectal tumor DNA was examined for somatic instability at (CA)n repeats on human chromosomes 5q, 15q, 17p, and 18q, and this instability was significantly correlated with the tumor's location in the proximal colon and with increased patient survival and loss of heterozygosity.